-
Under the agreements, MSN Laboratory will establish a manufacturing unit along with a Research & Development (R&D) center. Laurus Labs and Aurobindo Pharma will set up formulation units. Gland Pharma has shown interest in opening an R&D center, as well as manufacturing units for injectables and drug substances. Dr. Reddy's Labs plans to establish a unit for injectables and biosimilars. Hetero Labs will set up a plant for finished dose and injectable manufacturing.
-
Hyderabad: Hyderabad-based pharma company Laurus Labs reported a profit after tax of Rs 251 crore for the June quarter. This is an increase of four per cent over last year. Its revenues were Rs 1,539 crore, up 20% over the corresponding period last year. Its earnings before interest, taxes, depreciation, and amortisation (EBITDA) was Rs […]
-
Hyderabad: West Pharmaceutical Services, which operates in injectable drug administration segment, appointed Ravikrishna Chebolu as GM of its India operations. While West’s global headquarter is in Exton, Pennsylvania, United States, in India the company has its sales office in Hyderabad, servicing customers throughout India. With over 20 years of relevant commercial and general management experience […]
-
Hyderabad: Laurus Labs reported a 44 per cent year-on-year dip in its net profit for the third quarter of FY22 at Rs 154 crore, while its total net revenue decreased 20 per cent year-on-year at Rs 1,029 crore. EBITDA saw a 33 per cent decline year-on-year at Rs 290 crore. For the nine months ended […]
-
Karimnagar: District Collector RV Karnan advised the people on Tuesday to utilise the medical and other facilities provided in the district headquarters government hospital. The Collector was speaking after inaugurating a 12 bed ICU ward constructed on the first floor of the district headquarters hospital. While Hyderabad-based firm Laurus Lab donated about Rs 30 lakh […]
-
Hyderabad: Continuing its efforts to support the pharma and life sciences segments, Government of Telangana State together with pharma industry players announced a new Centre of Excellence (CoE) on Flow Chemistry in Hyderabad. This initiative is aimed towards ensuring greater incorporation of flow chemistry techniques during pharma research and development and greater adoption of continuous […]
-
Hyderabad: Laurus Labs has signed an investment agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company to acquire 26.62 per cent stake (fully diluted basis) for a cash consideration of approximately Rs 46 crore, subject to the fulfilment of certain conditions. Additionally, senior management of Laurus Labs would also […]
-
Hyderabad: Hyderabad-based Laurus Labs, Unitaid and the Clinton Health Access Initiative (CHAI) have partnered to accelerate the development, commercialisation, and registration of the second- and third-line HIV treatment darunavir boosted with ritonavir (DRV/r) for children. Despite being available in high-income countries for over a 15-year period, a generic, fixed-dose combination pediatric version of DRV/r is […]
-
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for the treatment of Covid-19 patients in the country.
-
Hyderabad-based company’s revenues for FY21 stood at Rs 4,814 crore, up 70 per cent Y-o-Y while its profit jumped 286 per cent to Rs 984 crore Y-o-Y
-
Instituted in 1991 by the Institute of Directors (IOD), India, the Golden Peacock Award is regarded as a global recognition for corporate excellence.
-
The company’s revenue grew by 76 per cent at Rs 1,288 crore as against Rs 730 crore in the year-ago period.
-
Hyderabad-based company to acquire 72.55% stake in Bengaluru biotech firm for over Rs 246 crore
-
The company’s revenue for the first half of the fiscal went up to Rs 2,113 crore, up 67 per cent Y-o-Y, while net profit jumped 475 per cent to Rs 414 crore Y-o-Y.
-
Minister said the State government was attracting investments even during the Covid-19 pandemic due to its continuous efforts over a period of time
-
Granules India, Laurus Labs to set up new manufacturing facilities for finished dosages and formulations, respectively
